Clenziderm Pore Therapy

Description

OBAGI® MEDICAL CLENZIderm M.D.™ Pore Therapy is an acne treatment formulation containing 2% salicylic acid. This product is designed to target and help reduce the appearance of pores. It is available in a dosage form of 5 fluid ounces (148 mL).

Uses and Indications

This drug is indicated for the treatment of acne. It effectively dries up acne pimples and helps prevent the formation of new acne pimples.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleansed prior to the application of this product. It is essential to shake the product well before use to ensure proper mixing of the formulation.

The product should be applied as a thin layer to the entire affected area. Initial dosing should consist of one application daily. Depending on the patient's response and as directed by a physician, the frequency may be gradually increased to two or three times daily.

It is important to monitor for signs of excessive drying of the skin. If bothersome dryness or peeling occurs, the application frequency should be reduced to once daily or every other day to mitigate these effects.

Contraindications

There are no specified contraindications for this product. However, it is advised to discontinue use and consult a healthcare professional if irritation becomes severe.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients that the application of this product may lead to skin irritation and dryness, particularly if used concurrently with other topical acne medications. To minimize the risk of irritation, it is recommended that patients use only one topical acne medication at a time.

In the event that severe irritation occurs, patients should be instructed to discontinue use immediately and consult a healthcare provider for further guidance.

It is imperative to keep this product out of reach of children. In cases of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center without delay.

Side Effects

Patients using this product should be aware that it is for external use only. Common adverse reactions include skin irritation and dryness, which are more likely to occur if another topical acne medication is used concurrently. In clinical practice, it is advised that if irritation occurs, patients should limit the use to one topical acne medication at a time to mitigate these effects.

In the event that irritation becomes severe, patients are instructed to stop use and consult a healthcare professional. Additionally, it is crucial to keep this product out of reach of children. If the product is swallowed, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to alleviate symptoms. Monitoring for signs of skin irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Clenziderm Pore Therapy (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of Clenziderm Pore Therapy Acne Treatment, including dosage adjustments, safety concerns, or special precautions. As such, healthcare providers should exercise caution when prescribing this treatment to geriatric patients.

Due to the absence of clinical findings or data specific to this population, it is advisable for healthcare providers to closely monitor elderly patients for any adverse effects or unusual responses to the treatment. Individualized assessment and consideration of the patient's overall health status and concurrent medications are recommended to ensure safe and effective use.

Pregnancy

There are no specific warnings or precautions regarding the use of CLENZIDERM PORE THERAPY during pregnancy. The available data does not indicate whether the product is contraindicated in pregnant patients or if there are any associated risks to the fetus. Healthcare professionals should consider the lack of specific information when advising women of childbearing potential and weigh the benefits against any potential risks when prescribing this therapy during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information provided regarding the potential for excretion in breast milk or any associated risk to breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the patient's overall health status and liver function.

Overdosage

In the event of an overdosage, immediate medical intervention is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical assistance or contact a Poison Control Center without delay.

Prompt action is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. Continuous monitoring and evaluation are advised to ensure patient safety and effective resolution of any complications arising from the overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event of swallowing the medication, patients should seek medical assistance or contact a Poison Control Center immediately.

Patients should be informed to discontinue use and consult a doctor if they experience severe irritation. It is important to note that the likelihood of skin irritation and dryness may increase if patients use another topical acne medication concurrently. Therefore, healthcare providers should recommend that patients use only one topical acne medication at a time to minimize the risk of irritation.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product away from heat and direct sunlight to maintain its integrity. The recommended storage conditions are at a controlled room temperature of 15°–25°C (59°–77°F). Proper adherence to these storage guidelines will ensure the product remains effective and safe for use.

Additional Clinical Information

The medication is administered topically, with a recommended application of a thin layer to the entire affected area one to three times daily. To minimize the risk of excessive skin drying, it is advised to begin with one application per day, gradually increasing to two or three times daily as necessary or as directed by a healthcare professional. Should patients experience bothersome dryness or peeling, they should reduce the frequency of application to once daily or every other day.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Clenziderm Pore Therapy, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)